Why does the answer depend on the individual?
This article concerns infection-prevention vaccination for adults with cancer. Cancer itself, treatment, previous vaccination and other health conditions can affect infection risk and the response to a vaccine. Chemotherapy, hormonal treatment, radiotherapy, immunotherapy and transplantation do not all have the same effects, so “cancer patient” is not a complete vaccination assessment. Children need a paediatric oncology plan.
There are two questions to answer separately: could the vaccine pose a safety problem in the current immune state, and how much protection is the person likely to develop? A reduced response does not automatically mean vaccination is unsafe or pointless. It means that the expected benefit and timing need to be weighed carefully.
What is the difference between the vaccine types?
Live attenuated vaccines contain weakened viruses or bacteria that can still replicate. In Hong Kong wording, these are 減活疫苗. Examples include MMR and live attenuated nasal influenza vaccine. They can pose an infection risk when immunity is significantly suppressed and should not be selected without a specialist assessment; the adult ASCO guideline advises against nasal live attenuated influenza vaccine for patients with cancer.
Vaccines without live pathogens are a broader group than inactivated vaccines alone. They include inactivated vaccines, recombinant vaccines and mRNA vaccines. The Chinese wording here is 不含活病原體的疫苗, with 滅活疫苗 used only for the inactivated subgroup. These products do not share the live-vaccine replication concern, but still need checks for individual contraindications and the likely immune response.
Can vaccination take place during treatment?
ASCO’s adult guideline supports giving suitable non-live vaccines during or after several cancer treatments, although the immune response can be weaker. It does not support a blanket statement that vaccination during chemotherapy is generally prohibited with influenza as the only exception. Where possible, review vaccination before planned treatment so the team can choose appropriate opportunities.
If treatment must begin urgently, do not postpone it to fit an online vaccination timetable. If treatment is already under way, raise the question now rather than assuming every vaccine must wait until all treatment is over. The treating team can decide which infection risks need attention and which doses should be given, deferred or reviewed later.
Why can there be a special plan after some treatments?
B-cell-depleting treatment can affect antibody responses. Stem-cell transplantation and CAR-T therapy can also require specific vaccination or revaccination arrangements. Previous vaccine records remain important, but they may not settle what protection is expected after these treatments. A general “wait six months” rule cannot describe all vaccines, therapies and stages of immune recovery.
Ask the oncology team to specify the vaccine, timing, who will administer it and whether a later review or repeat course is needed. This is particularly important when a community clinic can supply the vaccine but does not hold the full treatment record. Keep the agreed plan shared between the treating and vaccination teams.
What should I take to the discussion?
Bring the treatment names and dates, current medicines, transplant or CAR-T information where relevant, previous vaccine records and serious reaction history. Ask which vaccines are due, what benefit is expected now, what should be avoided, and whether household members need advice about their own vaccinations. Household vaccination can support protection, but does not replace the patient’s plan.
Finally, confirm Hong Kong product availability, approved uses and any funding eligibility separately. ASCO provides adult clinical guidance; it does not establish which Hong Kong clinic has stock or which government programme will pay. The next step is a coordinated, individual vaccination plan, not self-booking from a general cancer label.